Cadonilimab

DB16680InvestigationalProtein Based Therapies

Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4 and Programmed cell death protein 1
Curator reviewed
Also known as: Cardenilimab · Cardonilizumab
Code names: AK-104 · Anti-PD1/Anti-CTLA4 bispecific antibody AK104 · PD-1 x CTLA-4 dual checkpoint inhibitor AK104

Resolves to

Compound

UNII6FYG1DS4NWCAS2394841-59-7

Targets

P16410CTLA4Q15116PDCD1

What you can answer from here — as of July 20, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

202Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cadonilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account